CTOs on the Move

Moderna Therapeutics

www.modernatx.com

 
Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.modernatx.com
  • 200 Technology Square
    Cambridge, MA USA 02139
  • Phone: 617.714.6500

Executives

Name Title Contact Details
Brad Miller
Chief Information Officer Profile
Marcello Damiani
Chief Digital Officer Profile
Jerh Collins
Chief Technical Operations and Quality Officer Profile
Adrian Stone
Senior Vice President and Chief Information Security Officer Profile

Funding

Moderna Therapeutics raised $650M on 01/12/2016
Moderna Therapeutics raised $483M on 04/17/2020
Moderna Therapeutics raised $472M on 07/24/2020

Similar Companies

IntelligentMDx

IntelligentMDx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARCA biopharma

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.

Odyssey Research Services

Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northwest Biotherapeutics

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio`s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company`s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company`s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

The Degge Group

The Degge Group is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.